

Freedom of Information Request - 4238

Please indicate the number of metastatic or locally advanced Urothelial cancer patients treated by your Trust in the 3 months, April 2018 to June 2018 inclusive.

	Total number treated (Metastatic/locally advanced Urothelial patients)	If unable to provide number of metastatic/locally advanced Urothelial patients, please indicate the level at which data has been provided:	
Total number of metastatic or locally advanced Urothelial cancer (UCC, transitional carcinoma, TCC) patients treated	4	Total Urothelial Cancer patients (any stage)	
		Other (please specify)	
		Data not held/accessible	

Of the metastatic or locally advanced Urothelial cancer patients treated by your Trust in the 3 months, April 2018 to June 2018 inclusive, please indicate the number treated with the following therapies.

Therapy	Total number treated (Metastatic/locally advanced Urothelial patients)	If unable to provide number of metastatic/locally advanced Urothelial patients, please indicate the level at which data has been provided:	
Cisplatin (mono or combination therapy)	2	Total Urothelial Cancer patients (any stage)	
		Other (please specify)	
		Data not held/accessible	
Carboplatin (mono or combination therapy)	N/A	Total Urothelial Cancer patients (any stage)	
		Other (please specify)	
		Data not held/accessible	
Pembrolizumab (Keytruda)	N/A	Total Urothelial Cancer patients (any stage)	
		Other (please specify)	
		Data not held/accessible	
Atezolizumab (Tecentriq)	1	Total Urothelial Cancer patients (any stage)	
		Other (please specify)	
		Data not held/accessible	

If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust(s) patients are referred: **N/A**